Transplant Statistics: Annual Report

	Year of Transplant
	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Total # of Post-Tx Malignancies	123	161	143	141	154	122	86	70	27	9
Malignancies by Type	78	110	80	93	93	82	56	47	17	6
Squamous/Basal Cell Carcinoma
Melanoma	2	-	3	2	4	2	4	4	1	-
Kaposi Sarcoma	-	-	-	-	-	1	-	2	-	-
Central Nervous System	2	-	-	1	2	-	-	-	-	-
Genito-Urinary (1)	4	5	10	5	5	5	4	3	3	-
Gastro-Intestinal (2)	22	16	19	16	15	16	9	7	1	2
Primary Hepatic Tumor	-	-	2	-	1	-	-	-	1	-
Metastatic Hepatic Tumor	1	2	3	3	-	1	2	-	1	-
Larynx/Bronchi/Lung	9	13	13	5	16	6	6	3	3	-
Breast/Thyroid/Adrenal	1	1	2	-	5	3	4	1	-	-
Leukemia	1	1	2	2	-	-	-	1	-	-
Sarcoma (3)	-	4	-	2	4	1	-	-	-	-
Other	3	9	8	12	8	4	1	1	-	1
Unknown	-	-	1	-	1	1	-	1	-	-
Malignancies by Type(%)	63.4%	68.3%	55.9%	66.0%	60.4%	67.2%	65.1%	67.1%	63.0%	66.7%
Squamous/Basal Cell Carcinoma
Melanoma	1.6%	-	2.1%	1.4%	2.6%	1.6%	4.7%	5.7%	3.7%	-
Kaposi Sarcoma	-	-	-	-	-	0.8%	-	2.9%	-	-
Central Nervous System	1.6%	-	-	0.7%	1.3%	-	-	-	-	-
Genito-Urinary (1)	3.3%	3.1%	7.0%	3.5%	3.2%	4.1%	4.7%	4.3%	11.1%	-
Gastro-Intestinal (2)	17.9%	9.9%	13.3%	11.3%	9.7%	13.1%	10.5%	10.0%	3.7%	22.2%
Primary Hepatic Tumor	-	-	1.4%	-	0.6%	-	-	-	3.7%	-
Metastatic Hepatic Tumor	0.8%	1.2%	2.1%	2.1%	-	0.8%	2.3%	-	3.7%	-
Larynx/Bronchi/Lung	7.3%	8.1%	9.1%	3.5%	10.4%	4.9%	7.0%	4.3%	11.1%	-
Breast/Thyroid/Adrenal	0.8%	0.6%	1.4%	-	3.2%	2.5%	4.7%	1.4%	-	-
Leukemia	0.8%	0.6%	1.4%	1.4%	-	-	-	1.4%	-	-
Sarcoma (3)	-	2.5%	-	1.4%	2.6%	0.8%	-	-	-	-
Other	2.4%	5.6%	5.6%	8.5%	5.2%	3.3%	1.2%	1.4%	-	11.1%
Unknown	-	-	0.7%	-	0.6%	0.8%	-	1.4%	-	-
Total # of Patients	84	117	113	110	112	93	73	57	21	8

Source: OPTN/SRTR Data as of August 1, 2001.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Patients may have more than one posttransplant malignancy reported due to multiple follow-up forms.